Cotización Calithera Biosciences - CALA | ADVFN

US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Calithera Biosciences Inc (CALA) Cotización

Calithera Biosciences Inc (CALA)

0.20

0.00

(0.00%)

Cerrado 01 Diciembre 3:00PM

Delayed by 15 minutes

0.00

0.00

(0.00%)

Fuera de horario: -

Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Último Precio

0.20

Postura de Compra

0.16

Postura de Venta

0.35

Volume Operado de la Acción

-

0.00 Rango del Día 0.00

0.00 Rango de 52 semanas 0.00

Capitalización de Mercado [m]

Precio Anterior

0.20

Precio de Apertura

-

Hora

Última hora de negociación

Volumen financiero

-

Precio Promedio Ponderado

-

Volumen promedio (3 m)

-

Acciones en circulación

4,872,497

Rendimiento del Dividendo

-

Ratio Precio/Utilidad

0.00

Beneficio por acción (BPA)

-4.37

turnover

-

Beneficio neto

-21.29M

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumo... Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.calithera.com

Sede

Wilmington, Delaware, USA

Fundado

-

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: “CALA”). Calithera Biosciences, Inc. (the “Company”) announced that it was unable to achieve a...

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or...

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive...

Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
BSLKBolt Projects Holdings Inc	US$ 0.71 (139.86%)	80.81M
PRZOParaZero Technologies Ltd	US$ 1.24 (94.14%)	205.02M
AIEVThunder Power Holdings Inc	US$ 0.47 (87.25%)	122.71M
PASGPassage Bio Inc	US$ 1.13 (69.52%)	15.44M
EPOWSunrise New Energy Company Ltd	US$ 1.06 (45.21%)	314.9k
APLTApplied Therapeutics Inc	US$ 2.03 (-76.31%)	43.9M
TGLTreasure Global Inc	US$ 0.2944 (-29.08%)	1.85M
PROCProcaps Group SA	US$ 1.51 (-27.75%)	106.08k
SHOTWSafety Shot Inc	US$ 0.104 (-20.00%)	1.43k
MONDMondee Holdings Inc	US$ 0.7102 (-19.59%)	297.63k
PRZOParaZero Technologies Ltd	US$ 1.24 (94.14%)	205.02M
NVDANVIDIA Corporation	US$ 138.25 (2.15%)	141.86M
AIEVThunder Power Holdings Inc	US$ 0.47 (87.25%)	122.71M
RGTIRigetti Computing Inc	US$ 3.05 (27.08%)	116.98M
MARAMARA Holdings Inc	US$ 27.42 (1.86%)	89.54M

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 años hace

maybe soon will see something

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 años hace

maybe soon will see something

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 años hace

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2 años hace

cala soon something

Renee

Renee 2 años hace

CALA delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

kzivann

kzivann 2 años hace

CALA dissolving. https://quantisnow.com/insight/3950020

Mr. Zen

Mr. Zen 2 años hace

Calithera continued to advance multiple vacuolar protein sorting-associated protein 4A (VPS4A) and VPS4B inhibitors through lead optimization and plans to share updates on this program by the end of 2022.

Nealio

Nealio 2 años hace

CALA - continues upward. 100% gain in last month, very good swing play. Drug data was good...float is very low at 4.X M shares.

Nealio

Nealio 2 años hace

CALA in play! Drug data and earnings report. Should move even higher on this news.

Nealio

Nealio 2 años hace

Chart looks very good atm.

Nealio

Nealio 2 años hace

Could be the start of a big run; or not. We shall see; with recent good news, I like the chances. Good luck to all!

ttottip

ttottip 3 años hace

ttottip

ttottip 3 años hace

Good morning all! Hoping for a reversal today.

ttottip

ttottip 3 años hace

I'm not hesitating to buy at these levels!

bandit007

bandit007 3 años hace

Took a few here. $CALA

kzivann

kzivann 3 años hace

Moving after hours.

CALA

crudeoil24

crudeoil24 3 años hace

Calithera Biosciences shares are trading higher after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and a $4 price target.

CALA

TheFinalCD

TheFinalCD 3 años hace

big move 45-74

$CALA

glens0

glens0 3 años hace

$CALA .58 w/ $3 price upgrade out by Leerink

Eagle1

Eagle1 3 años hace

crudeoil24

crudeoil24 3 años hace

Company discontinued its KEAPSAKE clinical trial.

Eagle1

Eagle1 3 años hace

Hi why the drop here?

0210

0210 3 años hace

Calithera Biosciences CALA Q3 EPS $(0.15) Beats $(0.23) Estimate, Sales $6.75M, and a 53.13 percent increase over losses of $(0.32) per share from the same period last year.

4:42 pm ET November 9, 2021 (Benzinga)
Calithera Biosciences (NASDAQ:CALA) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 53.13 percent increase over losses of $(0.32) per share from the same period last year. The company reported $6.75 million in sales this quarter.

0210

0210 3 años hace

right-on-the-money...-54% to $0.86-0.87, from $1.90 on 21x dmav (of only 1,082,848 daily moving average volume).

SOURCE: https://ih.advfn.com/stock-market/NASDAQ/calithera-biosciences-CALA/historical

willlbone

willlbone 3 años hace

Bid at 60% drop.

TheFinalCD

TheFinalCD 3 años hace

$CALA -40%

Calithera Biosciences, Inc. | Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

https://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-announces-decision-discontinue-keapsake

Elgordo84

Elgordo84 4 años hace

I’m expecting earnings to be on the up tomorrow
Let’s go $CALA

Elgordo84

Elgordo84 4 años hace

Looks like no one is paying attention
$CALA I guess is you and me!!!
Perfect for the run
While no one is watching.......

Elgordo84

Elgordo84 4 años hace

Ok hello $CALA
I LIKE WHAT I SEE HERE!!!!
Let’s take this for a ride...
$CALA LETS GO —————>

trade-stock000

trade-stock000 4 años hace

Cala when is the data due date? Thx

oaps222

oaps222 4 años hace

Thanks for the info.
Geez~~, what a move. I wish I knew it last Thursday! LOL

In any event, congratulations, if you already got in ARTL!

trade-stock000

trade-stock000 4 años hace

A-R-T-L is the one to watch (: PT $8-10
Add on correction price, read few post over there abt data and cocrystal CBD molecules. Apart from that it's focused on Lipid therapy the next frontier in Oncology.

oaps222

oaps222 4 años hace

Very good point, but be careful. The market is crazy. I can see some (big?) corrections in the near future.

oaps222

oaps222 4 años hace

From the recent 13G Filings, Adage Capital has reported its 4,000,000 shares of CALA (5.67% ownership) on Jan 13, 2021.

trade-stock000

trade-stock000 4 años hace

Yeah but in Jan that was not much of an update, that´s why stock plummeted, company needs more time.

Jan option price rose becoz of that reason, now fade out. Will visit this ticker later, for now it´s waste of cash esp when whole market is running nut

oaps222

oaps222 4 años hace

Was it on Jan 15-17, not Feb 15-17?
http://www.calithera.com/wp-content/uploads/2021/01/Arginase-1158-203-Poster.pdf

trade-stock000

trade-stock000 4 años hace

IV surges in the event of future price move. $5 call for Feb 19 it seems someone very bullish abt this stock and bot calls. Article u cited it's from Jan-13th, today its 13th Feb (:, unless next week something comes out which is highly unlikely.

oaps222

oaps222 4 años hace

I was doing a DD on CALA and found the following. I don't quite understand it. Can you share your thoughts on this?
"Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options"

https://finance.yahoo.com/news/implied-volatility-surging-calithera-biosciences-134001483.html

trade-stock000

trade-stock000 4 años hace

2.42 or lower test first before go up i hope

trade-stock000

trade-stock000 4 años hace

CALA on Feb 15-17 presenting Biliary-Tract Cancer-Data-could do-vroomvroom

jondoeuk

jondoeuk 4 años hace

ASH abstract https://ash.confex.com/ash/2020/webprogram/Paper137266.html

ClayTrader

ClayTrader 5 años hace

* * $CALA Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

cashbyers

cashbyers 5 años hace

9.5M block trade today @ $4.45.. 17% stake or $42M investment...

ClayTrader

ClayTrader 5 años hace

* * $CALA Video Chart 11-19-19 * *

Link to Video - click here to watch the technical chart video

jonny_red

jonny_red 5 años hace

4 Penny Stocks To Watch In November After Latest Milestones

$GTBP $CALA $AVDL $BLCM

https://www.transparenttraders.me/2019/11/4-penny-stocks-to-watch-in-november.html

cashbyers

cashbyers 5 años hace

Long CALA @ $2.60

buypumps

buypumps 5 años hace

Conference call Monday also. Could push to 3.90 area.

Zmill

Zmill 5 años hace

TA of CALA https://msmoneymoves.com/2019/07/12/calithera-initiates-potential-buying-opportunity/

CashBowski

CashBowski 5 años hace

CALA going to close the gap today.

Zmill

Zmill 5 años hace

Research mentioning CALA https://wordpress.com/block-editor/post/msmoneymoves.com/11262

Calithera Biosciences

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones